Colistin (polymyxin E) has been increasingly used worldwide as an antibiotic of last resort for infections caused by carbapenem-resistant Gram-negative bacteria. However, since the first report in China in 2016 [@bib1], occurrence of plasmid-mediated colistin resistance gene *mcr-*1 has been described in *Enterobacteriaceae* from animals and humans in Europe, the Americas, Australia and Asia [@bib2]. In Myanmar, *mcr-*1 has not yet been reported, although this gene has been detected in most of its neighbouring countries.

For the surveillance of carbapenem-resistant *Enterobacteriaceae,* a total of 1555 clinical isolates were collected at the North Okkalapa General Hospital, Yangon, Myanmar, from January to October 2018 ([Supplementary Table S1](#appsec1){ref-type="sec"}). Among a total of 442 isolates of *Escherichia coli,* 57 isolates (12.9%) were judged to be resistant to carbapenems by the disc diffusion test and were further analysed for the presence of *mcr* genes by PCR as described previously [@bib3]. As a result, *mcr-1* was detected in only one isolate (MMR-CR4) derived from a urine sample of a 68-year-old female inpatient with a urinary tract infection. MMR-CR4 was resistant to multiple classes of antimicrobials, including quinolone (levofloxacin), but was susceptible to fosfomycin and tigecycline ([Table 1](#tbl1){ref-type="table"}, [Supplementary Table S2](#appsec1){ref-type="sec"}). This isolate was judged to be resistant to ertapenem and colistin with low minimum inhibitory concentrations, but showed susceptibility to imipenem and meropenem.Table 1Antimicrobial resistance and genetic traits of *Escherichia coli* isolate MMR-CR4 in MyanmarTable 1CharacteristicValueResistance profilePIP, CEZ, CTM, CTX, CPD, SAM, ATM, ETP, GEN, MIN, SXT, LVX, COLPhylogenetic groupASTST90 SLV (ST23Cplx)[a](#tbl1fna){ref-type="table-fn"}Virulence factor genes[b](#tbl1fnb){ref-type="table-fn"}*fimH, fyuA, traT, iroN, iha, astA*β-Lactamase genes (*bla*)[c](#tbl1fnc){ref-type="table-fn"}CTX-M-15, TEM-1Colistin resistance gene[c](#tbl1fnc){ref-type="table-fn"}*mcr-1*Aminoglycoside-modifying enzyme gene[c](#tbl1fnc){ref-type="table-fn"}*aph*(*3′*)*-IIIa, ant*(*4′*)*-Ia*PMQR gene[c](#tbl1fnc){ref-type="table-fn"}*qnrS, oqxAB*Mutation in QRDR *gyrA*S83L, D87N *parC*S80I FimH subtype*fimH*142[^1][^2][^3][^4]

*E. coli* isolate MMR-CR4 was classified into phylogenetic group A, single-locus variant of sequence type (ST) 90 (ST23 complex) and *fimH* subtype 142. Presence of *mcr-1, bla*~CTX-M-15~ and *bla*~TEM-1~ was confirmed by determination of sequences (GenBank accession nos. MK405590--MK405592), although no carbapenemase gene was detected. This isolate harboured two aminoglycoside-modifying enzyme genes and two plasmid-mediated quinolone resistance genes. In the quinolone-resistance--determining region of *gyrA* and *parC,* two and one mutations were detected, respectively.

In this study, *mcr-1* was detected in *E. coli* for the first time in Myanmar, with a low prevalence among carbapenem-resistant isolates (1/57, 1.8%), which was comparable to those reported for sporadic human cases in other countries [@bib2], [@bib4]. The isolate MMR-CR4 harboured no carbapenemase gene, but it was a carbapenem-resistant *Enterobacteriaceae* showing multiple-drug resistance. Although ST23 complex has been scarcely identified among *E. coli* harbouring *mcr-1* in humans and animals [@bib5], [@bib6], only ST410 (ST23 complex) was described in *mcr-1*--positive clinical isolates in China [@bib7].

We recently reported that phylogroup A/ST23 complex was a common lineage of *E. coli* in Myanmar [@bib8] and Bangladesh [@bib9], and some clones had carbapenemase genes such as *bla*~NDM-1~. Furthermore, ST23 complex, represented by ST90 and ST410, was described as one of the major lineages of carbapenemase-producing *E. coli* in Europe, and the origin of a portion of isolates was suspected to be South Asian or Southeast Asian countries [@bib10]. Accordingly, there is a concern that *mcr-1*--positive, ST23 complex *E. coli* will acquire the carbapenemase gene, becoming an extremely drug-resistant clone. In addition, MMR-CR4 had multiple mutations in quinolone-resistance--determining regions in *gyrA* and *parC,* as identified in Austria [@bib11], thus suggesting its selective increase with the use of quinolones. Despite its low prevalence, the presence of *mcr-1* in a clinical isolate in Myanmar should be noted as sign of spread of multidrug resistance in *Enterobateriaceae.*
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Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nmni.2019.100550>.

[^1]: ATM, aztreonam; CFZ, cefazolin; COL, colistin; CPD, cefpodoxime; CTM, cefotiam; CTX, cefotaxime; ETP, ertapenem; GEN, gentamycin; LVX, levofloxacin; MIN, minocycline; PIP, piperacillin; PMQR, plasmid-mediated quinolone resistance; QRDR, quinolone-resistance determining region; SAM, ampicillin/sulbactam; SLV, single-locus variant; ST, sequence type; SXT, sulfamethoxazole/trimethoprim.

[^2]: Allelic profile of ST: 6-4-4-1-20-8-7.

[^3]: Negative for *PAI, papAH, kpsMTIII, ibeA, sfa/focDC, kpsMT-K1, hlyA, kpsMTII, papC, cdtB, focG, afa/draBC, cnf1, kpsMT K5, iutA, ireA, chuA, vat, hra, sat, clbB, pic, usp*.

[^4]: Negative for *bla* encoding SHV, NDM, IMP, VIM, KPC, SPM, SIM, GIM, GES, IMI, DIM, BIC, AIM, SME, NMC, OXA-23, OXA-24, OXA-48, OXA-51, AmpC and also for *aac-6′-aph 2″, aac-6′-Ib-cr, mcr-2, mcr-3, mcr-4, mcr-5,qnrA, qnrB, qnrC, qnrD, qepA*.
